Targeting IL8 As a Sequential Therapy Strategy to Overcome Chemotherapy Resistance in Advanced Gastric Cancer

Overview

Journal Cell Death Discov

Date 2022 Apr 29

PMID 35487914

Authors

Huning Jiang

Jiahua Cui

Hao Chu

Tingting Xu

Mengyan Xie

Xinming Jing

Jiali Xu

Jianwei Zhou

Yongqian Shu

Affiliations

Soon will be listed here.

Abstract

Systemic chemotherapy with multiple drug regimens is the main therapy option for advanced gastric cancer (GC) patients. However, many patients develop relapse soon. Here, we evaluated the therapeutic potential of targeting interleukin-8 (IL8) to overcome resistance to chemotherapy in advanced GC. RNA sequencing revealed crucial molecular changes after chemotherapy resistance, in which the expression of IL8 was significantly activated with the increase in drug resistance. Subsequently, the clinical significance of IL8 expression was determined in GC population specimens. IL8-targeted by RNA interference or reparixin reversed chemotherapy resistance with limited toxicity in vivo and vitro experiments. Sequential treatment with first-line, second-line chemotherapy and reparixin inhibited GC growth, reduced toxicity and prolonged survival. Collectively, our study provides a therapeutic strategy that targeting IL8 as a sequential therapy after chemotherapy resistance in advanced GC.

Citing Articles

Tumor‑associated neutrophils: Critical regulators in cancer progression and therapeutic resistance (Review).

Hou R, Wu X, Wang C, Fan H, Zhang Y, Wu H Int J Oncol. 2025; 66(4).

PMID: 40017131 PMC: 11900975. DOI: 10.3892/ijo.2025.5734.

Interleukin-8/CXCR1 Signaling Contributes to the Progression of Pulmonary Adenocarcinoma Resulting in Malignant Pleural Effusion.

Chang Y, Huang W, Yang S, Jan C, Nieh S, Lin Y Cells. 2024; 13(11.

PMID: 38891100 PMC: 11172099. DOI: 10.3390/cells13110968.

Doxorubicin and folic acid-loaded zinc oxide nanoparticles-based combined anti-tumor and anti-inflammatory approach for enhanced anti-cancer therapy.

Gomaa S, Nassef M, Tabl G, Zaki S, Abdel-Ghany A BMC Cancer. 2024; 24(1):34.

PMID: 38178054 PMC: 10768430. DOI: 10.1186/s12885-023-11714-4.

Cytokine-mediated crosstalk between cancer stem cells and their inflammatory niche from the colorectal precancerous adenoma stage to the cancerous stage: Mechanisms and clinical implications.

Cui G, Wang Z, Liu H, Pang Z Front Immunol. 2022; 13:1057181.

PMID: 36466926 PMC: 9714270. DOI: 10.3389/fimmu.2022.1057181.

Adenosine signaling: Optimal target for gastric cancer immunotherapy.

Wang J, Du L, Chen X Front Immunol. 2022; 13:1027838.

PMID: 36189223 PMC: 9523428. DOI: 10.3389/fimmu.2022.1027838.

References

Drilon A, Siena S, Ou S, Patel M, Ahn M, Lee J . Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 2017; 7(4):400-409. PMC: 5380583. DOI: 10.1158/2159-8290.CD-16-1237. View

Qi W, Zhang Q, Wang J . CXCL8 is a potential biomarker for predicting disease progression in gastric carcinoma. Transl Cancer Res. 2022; 9(2):1053-1062. PMC: 8797801. DOI: 10.21037/tcr.2019.12.52. View

Ajani J, DAmico T, Almhanna K, Bentrem D, Chao J, Das P . Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016; 14(10):1286-1312. DOI: 10.6004/jnccn.2016.0137. View

Ha H, Debnath B, Neamati N . Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases. Theranostics. 2017; 7(6):1543-1588. PMC: 5436513. DOI: 10.7150/thno.15625. View

Dummer R, Lebbe C, Atkinson V, Mandala M, Nathan P, Arance A . Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. Nat Med. 2020; 26(10):1557-1563. DOI: 10.1038/s41591-020-1082-2. View

Reusch T, Baums I, Werner B . Evolution via somatic genetic variation in modular species. Trends Ecol Evol. 2021; 36(12):1083-1092. DOI: 10.1016/j.tree.2021.08.011. View

Persi E, Wolf Y, Horn D, Ruppin E, Demichelis F, Gatenby R . Mutation-selection balance and compensatory mechanisms in tumour evolution. Nat Rev Genet. 2020; 22(4):251-262. DOI: 10.1038/s41576-020-00299-4. View

Kang J, Lee S, Lim D, Park K, Oh S, Kwon H . Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 2012; 30(13):1513-8. DOI: 10.1200/JCO.2011.39.4585. View

Dieci M, Guarneri V, Tosi A, Bisagni G, Musolino A, Spazzapan S . Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial. Clin Cancer Res. 2021; 28(2):308-317. PMC: 9401542. DOI: 10.1158/1078-0432.CCR-21-2260. View

10.

Liu Q, Li A, Tian Y, Wu J, Liu Y, Li T . The CXCL8-CXCR1/2 pathways in cancer. Cytokine Growth Factor Rev. 2016; 31:61-71. PMC: 6142815. DOI: 10.1016/j.cytogfr.2016.08.002. View

11.

Jin H, Shi Y, Lv Y, Yuan S, Ramirez C, Lieftink C . EGFR activation limits the response of liver cancer to lenvatinib. Nature. 2021; 595(7869):730-734. DOI: 10.1038/s41586-021-03741-7. View

12.

Schott A, Goldstein L, Cristofanilli M, Ruffini P, McCanna S, Reuben J . Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2-Negative Metastatic Breast Cancer. Clin Cancer Res. 2017; 23(18):5358-5365. PMC: 5600824. DOI: 10.1158/1078-0432.CCR-16-2748. View

13.

Yeoh K, Tan P . Mapping the genomic diaspora of gastric cancer. Nat Rev Cancer. 2021; 22(2):71-84. DOI: 10.1038/s41568-021-00412-7. View

14.

Moriconi A, Cesta M, Cervellera M, Aramini A, Coniglio S, Colagioia S . Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2. J Med Chem. 2007; 50(17):3984-4002. DOI: 10.1021/jm061469t. View

15.

Allegretti M, Bertini R, Cesta M, Bizzarri C, Di Bitondo R, Di Cioccio V . 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005; 48(13):4312-31. DOI: 10.1021/jm049082i. View

16.

Schafer J, Lehmann B, Gonzalez-Ericsson P, Marshall C, Beeler J, Redman L . Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors. Sci Transl Med. 2020; 12(534). PMC: 7427123. DOI: 10.1126/scitranslmed.aaw8275. View

17.

David J, Dominguez C, Hamilton D, Palena C . The IL-8/IL-8R Axis: A Double Agent in Tumor Immune Resistance. Vaccines (Basel). 2016; 4(3). PMC: 5041016. DOI: 10.3390/vaccines4030022. View

18.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

19.

Thuss-Patience P, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K . Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011; 47(15):2306-14. DOI: 10.1016/j.ejca.2011.06.002. View

20.

New J, Arnold L, Ananth M, Alvi S, Thornton M, Werner L . Secretory Autophagy in Cancer-Associated Fibroblasts Promotes Head and Neck Cancer Progression and Offers a Novel Therapeutic Target. Cancer Res. 2017; 77(23):6679-6691. PMC: 5712244. DOI: 10.1158/0008-5472.CAN-17-1077. View